Cargando…

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells

BACKGROUND: Chemotherapy resistance presents a difficult challenge in treating epithelial ovarian cancer patients, particularly when tumors exhibit resistance to multiple chemotherapeutic agents. A few studies have shown that elevated serum levels of the ovarian cancer biomarker HE4 correlate with t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribeiro, J. R., Schorl, C., Yano, N., Romano, N., Kim, K. K., Singh, R. K., Moore, R. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869286/ https://www.ncbi.nlm.nih.gov/pubmed/27184254 http://dx.doi.org/10.1186/s13048-016-0240-0

Ejemplares similares

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth
por: Moore, Richard G., et al.
Publicado: (2014)

Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix
por: Ribeiro, Jennifer R., et al.
Publicado: (2018)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation
por: Lokich, Elizabeth, et al.
Publicado: (2014)

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis
por: Fruscio, R, et al.
Publicado: (2008)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein
por: Stordal, Britta, et al.
Publicado: (2012)

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
por: Mesquita, Bárbara, et al.
Publicado: (2005)

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
por: Sherman-Baust, Cheryl A, et al.
Publicado: (2011)

Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells
por: Szenajch, Jolanta, et al.
Publicado: (2020)

Paclitaxel and SN‐38 Overcome Cisplatin Resistance of Ovarian Cancer Cell Lines by Down‐regulating the Influx and Efflux System of Cisplatin
por: Komuro, Yuuki, et al.
Publicado: (2001)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

Quantitative Proteomic and Interaction Network Analysis of Cisplatin Resistance in HeLa Cells
por: Chavez, Juan D., et al.
Publicado: (2011)

Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers
por: Kim, Kyu Kwang, et al.
Publicado: (2015)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
por: Gamarra-Luques, Carlos D, et al.
Publicado: (2014)

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
por: Stathopoulos, G. P., et al.
Publicado: (2010)

Seizure following chemotherapy (paclitaxel and cisplatin) in a patient of carcinoma cervix
por: Dana, Rohitashwa, et al.
Publicado: (2016)

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
por: Goyeneche, Alicia A, et al.
Publicado: (2012)

Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
por: Gong, Li-Hua, et al.
Publicado: (2014)

Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells
por: van Haaften, Caroline, et al.
Publicado: (2015)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2
por: Zhang, Yaqing, et al.
Publicado: (2021)

Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature
por: Serkies, Krystyna, et al.
Publicado: (2011)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Thermodynamic properties of HE3-HE4 solutions with applications to the HE3-HE4 dilution refrigerator
por: Radebaugh, R
Publicado: (1967)

x-rays from antiprotonic $^{3}$He and $^{4}$He
por: Schneider, M, et al.
Publicado: (1991)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines
por: Kazmierczak, Dominika, et al.
Publicado: (2022)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells.
por: Zaffaroni, N., et al.
Publicado: (1998)

Pion absorption on $^{3}He$ and $^{4}He$ with emission of three energetic protons
por: Lehmann, A, et al.
Publicado: (1997)

Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6
por: James, Nicole E., et al.
Publicado: (2019)

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

TRP14 promotes resistance to cisplatin by inducing autophagy in ovarian cancer
por: Tan, Wen-Xi, et al.
Publicado: (2019)

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012)

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
por: Srinivasan, K. N, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5q6o0danj1nn3u6l3eejn35vcp